Lieve M. J. Naesens

This paper investigates the mechanism of 6-ethyl-modified 7-deazaadenosine (EDA) as a coronavirus inhibitor, showing it stalls viral polymerase without causing mutagenesis.

This paper develops optimized RNA polymerase II-driven minigenomes for Nipah virus to enable safer research and antiviral screening.

This paper identifies UB-ALT-P2, a P2X7R antagonist that reduces Alzheimer's disease pathology in mice by improving memory, reducing amyloid-beta and tau, and decreasing inflammation.

This paper identifies N-benzamides as inhibitors of influenza virus fusion, showing efficacy against H1 and H5 hemagglutinins with low EC50 values and high selectivity.

This study synthesizes and evaluates polycyclic amines as alternatives to adamantane in M2 channel inhibitors, identifying compounds effective against wild-type and mutant M2 channels and showing antiviral activity against human coronavirus 229E.

This study identifies mutations in influenza hemagglutinin that increase acid-stability and decrease cleavability, with implications for viral transmissibility and vaccine development.

This paper identifies Trypstatin, a Kunitz-type protease inhibitor that inhibits TMPRSS2 and related proteases, showing broad-spectrum antiviral activity against SARS-CoV-2, influenza, and other respiratory viruses.

This study evaluates amantadine analogs against influenza A viruses with M2S31N resistance, finding some inhibit viral entry and assembly while being tolerated in mice.

This paper identifies EPB-113, a guanidine-based inhibitor of coronavirus nsp15 endoribonuclease, which suppresses viral replication and selects for interferon-susceptible mutants.

This study shows that FTO affects m6A marking on SARS-CoV-2 RNA and correlates with COVID-19 severity in patients.